Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of COPD according to GOLD guidelines, and current COPD symptoms~* A current or previous smoking history equivalent to 10 or more packs per year (1 pack year = 20 cigarettes smoked per day for one year).~* Documented use of a short-acting inhaled bronchodilator (β2-agonist or anticholinergics) as reliever medication.~Exclusion Criteria:~* A history and/or current diagnosis of asthma.~* Patients who have experienced COPD exacerbation requiring hospitalisation and/or a course of antibiotics and/or a course of systemic steroid within 30 days (from end of exacerbation treatment) prior to Visit 1 and/or during the run-in period.~* A history and/or current diagnosis of atopic diseases such as allergic rhinitis or eczema before the age of 40.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Formoterol, then Salmeterol, then Placebo (Type: EXPERIMENTAL): Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Placebo Diskus and Placebo Turbuhaler
- Salmeterol, then Palcebo, then Formoterol (Type: EXPERIMENTAL): Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Placebo Diskus and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus
- Placebo, then Formoterol, then Salmeterol (Type: EXPERIMENTAL): Placebo Diskus and Placebo Turbuhaler first,then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
- Formoterol, then Placebo, then Salmeterol (Type: EXPERIMENTAL): Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Placebo Diskus and Placebo Turbuhaler, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
- Salmeterol, then Formoterol, then Placebo (Type: EXPERIMENTAL): Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Placebo Diskus and Placebo Turbuhaler
- Placebo, then Salmeterol, then Formoterol (Type: EXPERIMENTAL): Placebo Diskus and Placebo Turbuhaler first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus

Based on this trial design, predict the completion outcome and termination type (if applicable).